In the last trading session, 7.33 million Lineage Cell Therapeutics Inc (AMEX:LCTX) shares changed hands as the company’s beta touched 1.53. With the company’s per share price at $0.75 changed hands at $0.03 or 3.66% during last session, the market valuation stood at $170.15M. LCTX’s last price was a discount, traded about -53.33% off its 52-week high of $1.15. The share price had its 52-week low at $0.37, which suggests the last value was 50.67% up since then.

Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information

Instantly LCTX was in green as seen at the end of in last trading. With action 9.90%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 48.28%, with the 5-day performance at 9.90% in the green. However, in the 30-day time frame, Lineage Cell Therapeutics Inc (AMEX:LCTX) is 69.34% up.

Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -2.93%. The 2025 estimates are for Lineage Cell Therapeutics Inc earnings to decrease by -9.73%, but the outlook for the next 5-year period is at 9.01% per year.

Lineage Cell Therapeutics Inc (AMEX:LCTX)’s Major holders

BLACKROCK INC. holds the second largest percentage of outstanding shares, with 5.0629% or 9.56 million shares worth $9.53 million as of 2024-06-30.

Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. With 4.42 shares estimated at $3.29 million under it, the former controlled 1.93% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 1.85% of the shares, roughly 4.23 shares worth around $3.15 million.